Company Overview and News

61
UPDATE 1-Berkshire boosts Goldman, Teva stakes; buys more Apple

2h reuters
(Reuters) - Warren Buffett’s Berkshire Hathaway Inc (BRKa.N) boosted its investments in Goldman Sachs Group Inc (GS.N) and Israel’s Teva Pharmaceutical Industries Ltd (TEVA.TA) during the second quarter and confirmed it has expanded its already huge bet on iPhone maker Apple Inc (AAPL.O).
LBTY TEVA UAL GLSSP LBTYK LILAB VRSK JBK AAL TFG BRK.A LILAK WFCNP TEVVF GS CHTR AAPL GM DAL WFC GSC LBTYB AXTA LBTYA GSJ TEVJF GJS LILA

61
Berkshire boosts Goldman, Teva stakes; buys more Apple - Channel NewsAsia

5h channelnewsasia
Warren Buffett's Berkshire Hathaway Inc on Tuesday said it has increased its investment in Goldman Sachs Group Inc , and confirmed it has added to its stake in iPhone maker Apple Inc .
LBTY TEVA UAL GLSSP LBTYK LILAB VRSK JBK AAL TFG BRK.A LILAK WFCNP TEVVF GS CHTR AAPL GM DAL WFC GSC LBTYB AXTA LBTYA GSJ TEVJF GJS LILA

28
Is Cocrystal Beating The Dead Hepatitis C Horse?

18h seekingalpha
Cocrystal believes that there is still a suitable market for their ultra-short Hepatitis C regimen despite an industry-wide exodus out of Hepatitis C.
VRTX OPK GILD TEVA TEVVF BITRF VRX TEVJF TBPH SBPH ABBV PTCT COCP BMY ABBV

20
Here's Why Lilly (LLY) Stock is Up 15% Since Q2 Earnings

2018-08-13 zacks
Eli Lilly & Company’s (LLY - Free Report) stock has risen 15% since it announced second-quarter earnings on Jul 24.
FOX ARMO AMGN TEVJF TEVA NVS TEVVF LMHA LMHB FOXA LM

39
Your Daily Pharma Scoop: Strongbridge And United Reports Positive, Insmed AdCom Favored

2018-08-12 seekingalpha
Discussion: Strongbridge Biopharma plc (SBBP) announced positive results from a Phase 3 clinical trial of RECORLEV (levoketoconazole) in patients with endogenous Cushing's syndrome. The open-label trial met the primary endpoint. The endpoint was a achievement of mean urinary free cortisol by a statistically valid proportion of patients. This patient group included people who were in a post-six months maintenance treatment without a dose increase of RECORLEV.
SBBP AZN PRTK TEVA TEVVF LLY INSM TEVJF JNJ INSY AMPE UTHR

16
Red Flags Raised at Chinese Heart Drug Maker Year Before Recall - Bloomberg

2018-08-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
TEVJF TEVA TEVVF

17
Entera Bio Ltd. Announces Appointment of Mr. Gerald Lieberman as Chairman of the Board of Directors

2018-08-09 globenewswire
JERUSALEM, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX and ENTXW), announced today the appointment of Mr. Gerald Lieberman as the chairman of the board of directors, effective as of August 6, 2018.
TEVJF ENTX TEVA FRX TEVVF

16
Perrigo plans to separate prescription pharma business

2018-08-09 reuters
(Reuters) - Perrigo Co Plc (PRGO.N) said on Thursday it would separate its generics prescription business, which has been a drag on results, to focus on consumer healthcare following a strategic review, sending the drugmaker’s shares down about 8 percent.
TEVJF TEVA PRGO TEVVF

30
Your Daily Pharma Scoop: Foundation Promising, Paratek Moves Up, Ovid Down

2018-08-08 seekingalpha
Discussion: Foundation Medicine’s (FMI) announced a positive outcome of its bTMB assay. In a recent publication in Nature Medicine, a retrospective analysis of more than one thousand samples from NSCLC patients who participated in Roche (OTCQX:RHHBY) Genetech’s trials showed that use of Foundation Medicine’s (FMI) blood tumor mutational burden (‘bTMB) assay would have helped predict responses to TECENTRIQ (atezolizumab).
INO GILD PRTK TEVA OVID TEVVF ELTP SSKN PTIE MELA TEVJF EIGR PTGX FMI PFE

17
TEVA vs. TLGT: Which Stock Is the Better Value Option?

2018-08-07 zacks
Investors interested in Medical - Generic Drugs stocks are likely familiar with Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) and Teligent (TLGT - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
TEVJF TLGT TEVA TEVVF

70
Antares Pharma Appoints Dr. James Tursi Executive Vice President, Head of Research & Development, Chief Medical Officer

2018-08-06 globenewswire
EWING, N.J., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of James P. Tursi M.D. to the position of Executive Vice President, Head of Research & Development, Chief Medical Officer effective August 6, 2018. Dr. Tursi has a diversified corporate background including 15 years of drug development experience within the biotech and pharmaceutical industry.
ATRS AMAG TEVJF ARLZ AGRX POZN TEVA TEVVF AUXL

19
Antares Pharma Enters Into Development Agreement With Pfizer Inc.

2018-08-06 globenewswire
EWING, N.J., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) today announced that it has entered into an agreement with Pfizer Inc. (“Pfizer”) to develop a combination drug device rescue pen. This rescue pen will utilize the Antares QuickShot® auto injector and an undisclosed Pfizer drug. Pfizer will pay for the development of the product and will be responsible for obtaining FDA approval of the combination product.
ATRS AMAG PFZ TEVJF TEVA TEVVF 500680 PFE PFIZER

17
Teva (TEVA) Q2 Earnings Beat, Revenues Miss, Stock Down

2018-08-03 zacks
Teva Pharmaceutical Industries Limited (TEVA - Free Report) reported second-quarter 2018 earnings of 78 cents per share, which beat the Zacks Consensus Estimate of 67 cents per share. However, earnings per share declined 23.5% year over year.
AGN TEVJF TEVA NVS TEVVF

39
Top Analyst Upgrades and Downgrades: Blue Apron, Energy Transfer, Funko, Symantec, Teva, TripAdvisor and More

2018-08-03 247wallst
The major equity indexes were indicated marginally lower after the payrolls report looked light prior to adding in higher revisions. That said, the drops were small and the Nasdaq was indicated marginally positive. Investors have had less success buying the all the stock market dips in 2018 than in prior years. Many investors also are reconsidering how they want their investments positioned ahead of the midterm elections and with international trade concerns.
SYMC UAA TEVA TEVVF MS APRN RUN DATA TRIP SYF FUN EOG UA ETP TEVJF FNKO TRI FL

17
CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q2 2018 Results - Earnings Call Transcript

2018-08-03 seekingalpha
Good day, and welcome to the CTI BioPharma Second Quarter 2018 Financial Results Conference Call. Today’s conference is being recorded. At this time, I would like to turn the conference call over to Julia Balanova with Solebury Trout Investor Relations. Please go ahead.
TEVJF TEVA TEVVF CTIC CTI

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: EP0496760